Rosnilimab
Sponsors
Anaptysbio Inc., Anaptysbio Inc., Anaptysbio Inc., AnaptysBio, Inc.
Conditions
Alopecia AreataModerate to Severe Rheumatoid ArthritisRheumatoid ArthritisUlcerative Colitis
Phase 2
A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata
NCT05205070
Start: 2021-12-22End: 2023-03-19Target: 45Updated: 2022-05-10
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
Active, not recruitingNCT06041269
Start: 2023-08-31End: 2025-05-30Target: 420Updated: 2024-11-25
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
Active, not recruitingNCT06127043
Start: 2023-12-04End: 2026-05-31Target: 132Updated: 2025-10-03
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis
CompletedCTIS2023-504564-42-00
Start: 2024-04-08End: 2025-05-28Target: 200Updated: 2024-09-17
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Ulcerative Colitis
CompletedCTIS2023-508679-34-00
Start: 2024-07-30End: 2025-11-26Target: 93Updated: 2025-10-02